Evidence map›Paper›PMID 40295945›Full record

ArticleBMC cancer2025

HbA

Jonas Busk Holm, Jens Meldgaard Bruun, Peer Christiansen, Reimar Wernich Thomsen, Jan Frystyk, Deirdre Cronin-Fenton, Signe Borgquist

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jonas Busk HolmDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark. jonasbuskholm@oncology.au.dk.
Jens Meldgaard BruunDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Peer ChristiansenDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Reimar Wernich ThomsenDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Jan FrystykDepartment of Endocrinology, Odense University Hospital, Odense, Denmark.
Deirdre Cronin-FentonDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Signe BorgquistDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.

Funding

Kræftens Bekæmpelse R288-A16168Kræftens Bekæmpelse R327-A19070Novo Nordisk Foundation STENO Collaborative Grant NNF20OC0065928
6 · The paper itself

Abstract

backgroundDiabetes is associated with impaired breast cancer prognosis; however, the effectiveness of glycosylated hemoglobin (HbA

methodsThe study population comprised women with primary invasive stage I-III breast cancer between 2010 and 2020 surgically treated at Aarhus University Hospital, Denmark, without a diabetes diagnosis at baseline. We assessed HbA

resultsIn total, 2514 women (median age 62 years) were included. During median 5.6 years follow-up for new breast cancer events, 230 (9.1%) events occurred. An escalating risk of new breast cancer events was observed with increasing HbA

conclusionsFor women with primary breast cancer and no known diagnosis of diabetes, higher levels of HbA

Indexed as

Breast NeoplasmsGlycated HemoglobinAdultAgedBiomarkers, TumorDenmarkFemaleFollow-Up StudiesHumansMiddle AgedPrognosisBiomarkers, TumorGlycated Hemoglobinhemoglobin A1c protein, humanBreast cancerDiabetesHbA1cMetabolismPrognosis

Identifiers

PMID40295945
PMCPMC12036245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.